​

United Therapeutics (UTHR) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

UTHR Stock Forecast

United Therapeutics (UTHR) stock forecast, based on 30 Wall Street analysts, predicts a 12-month average price target of $579.83, with a high of $645.00 and a low of $447.00. This represents a 8.82% increase from the last price of $532.82.

$200 $290 $380 $470 $560 $650 High: $645 Avg: $579.83 Low: $447 Last Closed Price: $532.82

UTHR Stock Rating

United Therapeutics stock's rating consensus is Buy, based on 30 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 16 Buy (53.33%), 13 Hold (43.33%), 1 Sell (3.33%), and 0 Strong Sell (0.00%).

Buy
Total 30 1 13 16 Strong Sell Sell Hold Buy Strong Buy

UTHR Price Target Upside V Benchmarks

TypeNameUpside
StockUnited Therapeutics8.82%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts2315
Avg Price Target$612.50$623.33$526.07
Last Closing Price$532.82$532.82$532.82
Upside/Downside14.95%16.99%-1.27%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 26194--14
Feb, 26185--14
Jan, 26185--14
Dec, 25185--14
Nov, 25375--15
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 12, 2026Olivia BrayerCantor Fitzgerald$625.00$541.6015.40%17.30%
Feb 26, 2026Andrew FeinH.C. Wainwright$600.00$508.4718.00%12.61%
Jan 06, 2026UBS$645.00$506.7927.27%21.05%
Nov 19, 2025Eun YangJefferies$575.00$476.5920.65%7.92%
Oct 30, 2025Andrew FeinH.C. Wainwright$525.00$449.7616.73%-1.47%
Oct 30, 2025Lisa WalterRBC Capital$587.00$449.7630.51%10.17%
Oct 29, 2025Terrance FlynnMorgan Stanley$447.00$449.70-0.60%-16.11%
Oct 10, 2025Terence FlynnMorgan Stanley$435.00$445.38-2.33%-18.36%
Sep 29, 2025UBS$580.00$432.6634.05%8.85%
Sep 26, 2025RBC Capital$569.00$427.1633.21%6.79%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 12, 2026Cantor FitzgeraldOverweightOverweighthold
Mar 02, 2026JefferiesBuyBuyhold
Feb 26, 2026H.C. WainwrightBuyBuyhold
Feb 25, 2026Cowen & Co.BuyBuyhold
Feb 25, 2026Bank of America SecuritiesNeutralNeutralhold
Feb 17, 2026UBSBuyBuyhold
Jan 06, 2026UBSBuyBuyhold
Nov 19, 2025JefferiesBuyBuyhold
Oct 30, 2025H.C. WainwrightBuyBuyhold
Oct 30, 2025RBC CapitalOutperformOutperformhold

Financial Forecast

EPS Forecast

$10 $21 $32 $43 $54 $65 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$10.60$15.98$21.04$26.44$30.13---
Avg Forecast$11.38$17.52$19.75$24.31$28.54$29.58$39.69$34.70
High Forecast$12.10$18.72$21.10$28.47$34.53$41.57$61.71$37.76
Low Forecast$10.42$15.82$18.78$22.59$22.69$17.20$23.50$30.22
Surprise %-6.85%-8.79%6.53%8.76%5.57%---

Revenue Forecast

$2B $2B $3B $3B $4B $5B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.69B$1.94B$2.33B$2.88B$3.18B---
Avg Forecast$1.70B$1.96B$2.29B$2.88B$3.17B$3.37B$3.87B$4.11B
High Forecast$1.78B$2.07B$2.33B$2.95B$3.38B$3.38B$3.96B$4.39B
Low Forecast$1.59B$1.82B$2.26B$2.84B$2.87B$3.36B$3.78B$3.70B
Surprise %-0.73%-1.35%1.66%0.02%0.38%---

Net Income Forecast

$0 $700M $1B $2B $3B $4B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$475.80M$727.30M$984.80M$1.20B$1.33B---
Avg Forecast$484.39M$532.82M$984.80M$1.27B$1.30B$1.29B$1.61B$1.72B
High Forecast$581.26M$639.39M$1.18B$1.42B$1.72B$2.07B$3.07B$1.88B
Low Forecast$387.51M$426.26M$787.84M$1.12B$1.13B$854.73M$1.17B$1.50B
Surprise %-1.77%36.50%--5.83%2.34%---

UTHR Forecast FAQ

Is United Therapeutics stock a buy?

United Therapeutics stock has a consensus rating of Buy, based on 30 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 16 Buy, 13 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that United Therapeutics is a favorable investment for most analysts.

What is United Therapeutics's price target?

United Therapeutics's price target, set by 30 Wall Street analysts, averages $579.83 over the next 12 months. The price target range spans from $447 at the low end to $645 at the high end, suggesting a potential 8.82% change from the previous closing price of $532.82.

How does United Therapeutics stock forecast compare to its benchmarks?

United Therapeutics's stock forecast shows a 8.82% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for United Therapeutics over the past three months?

  • March 2026: 7.14% Strong Buy, 64.29% Buy, 28.57% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 7.14% Strong Buy, 57.14% Buy, 35.71% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 7.14% Strong Buy, 57.14% Buy, 35.71% Hold, 0% Sell, 0% Strong Sell.

What is United Therapeutics’s EPS forecast?

United Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $29.58, marking a -1.83% decrease from the reported $30.13 in 2025. Estimates for the following years are $39.69 in 2027, and $34.7 in 2028.

What is United Therapeutics’s revenue forecast?

United Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $3.37B, reflecting a 5.90% increase from the reported $3.18B in 2025. The forecast for 2027 is $3.87B, and $4.11B for 2028.

What is United Therapeutics’s net income forecast?

United Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $1.29B, representing a -3.34% decrease from the reported $1.33B in 2025. Projections indicate $1.61B in 2027, and $1.72B in 2028.